Dengue is a disease caused by a flavivirus that is transmitted principally by the bite of an
Aedes aegypti mosquito and represents a major public-health problem. Many studies have …

The evolution of antitumor therapies has significantly improved cancer prognosis but has
concurrently resulted in cardiovascular toxicities. Understanding the biological mechanisms …

Purpose Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor
that has been authorized for the treatment of non-small lung cancer; however, its …

Dengue is a disease caused by a flavivirus (DENV) and transmitted by the bite of a
mosquito, primarily the Aedes aegypti and Aedes albopictus species. Previous studies have …

Tivozanib is a triple vascular endothelial growth factor receptor inhibitor, recently approved
for the treatment of refractory advanced renal cell carcinoma. Clinical studies showed that …

The early myocardial response of hypertension is an elevation of angiotensin‐II (Ang‐II)
concentration, leading to heart failure and cardiac hypertrophy. This hypertrophic event of …

Background Ponatinib, a third-generation tyrosine kinase inhibitor, is employed in the
management of adult chronic myeloid leukemia. Nevertheless, the presence of process …

Here, we provide a review of the most clinically relevant cardiovascular toxicities to raise
awareness when caring for patients on these drugs. TKIs exemplify the complexity in …

Gefitinib (GEF) is an inhibitor of the epidermal growth factor receptor, linked to higher risk of
severe/fatal interstitial lung disease (ILD). This study was performed to determine the …

Ischemia–reperfusion injury (IRI) is a common pathogenic situation that arises throughout all
liver surgeries, including liver transplants. We aimed to compare the preventive effects of …